Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Furhan Yunus, MD, FACP
University of Tennessee
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Comprehensive Cancer Institute of Huntsville
Huntsville, Alabama, United States
- Little Rock Hematology-Oncology Associates
Little Rock, Arkansas, United States
- Pacific Coast Hematology/oncology Medical Group
Fountain Valley, California, United States
- Office of Alex J.P. Makalinao
Los Angeles, California, United States
- Hematology/oncology Group
Santa Rosa, California, United States
- University of Colorado Cancer Center
Denver, Colorado, United States
- Danbury Internal Medicine
Danbury, Connecticut, United States
- Comprehensive Cancer Care Specialists of Boca Raton
Boca Raton, Florida, United States
- Mercy Hospital
Miami, Florida, United States
- Mountain States Tumor Institute
Boise, Idaho, United States
- Memorial Medical Center
Springfield, Illinois, United States
- Carle Cancer Center
Urbana, Illinois, United States
- Indiana Community Cancer Care, Inc.
Indianapolis, Indiana, United States
- Cancer Health Associates
Michigan City, Indiana, United States
- North Mississippi Hematology and Oncology Associates, Ltd.
Tupelo, Mississippi, United States
- St. John'S Mercy Medical Center
St Louis, Missouri, United States
- Apn-Impath Research Corporation
Fort Lee, New Jersey, United States
- Overlook Hospital
Summit, New Jersey, United States
- Hemoncare, P.C.
Brooklyn, New York, United States
- Interlakes Oncology/hematology Pc
Rochester, New York, United States
- N.W. Carolina Oncology & Hematology, P.A.
Hickory, North Carolina, United States
- Oklahoma Oncology Inc.
Tulsa, Oklahoma, United States
- Rittenhouse Hematology/oncology
Philadelphia, Pennsylvania, United States
- South Carolina Oncology Associates
Columbia, South Carolina, United States
- Office of C. Michael Jones
Germantown, Tennessee, United States
- Boston Baskin Cancer Group, University Tennessee Oncology/hematology Group
Memphis, Tennessee, United States
- University of Tennessee, Memphis
Memphis, Tennessee, United States
- Arlington Cancer Center
Arlington, Texas, United States
- Southwest Regional Cancer Center
Austin, Texas, United States
- Intermountain Hematology/oncology Associates, Inc.
Salt Lake City, Utah, United States
- Northern Virginia Oncology Group, P.C.
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2000
- Primary completion
- —
- Completion
- 31 Oct 2005
- Last update posted
- 7 Jun 2012
- Registered enrollment
- —
- Registry id
- NCT00006459
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.